Catherine Granier

1.4k total citations · 1 hit paper
10 papers, 976 citations indexed

About

Catherine Granier is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Catherine Granier has authored 10 papers receiving a total of 976 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Infectious Diseases, 7 papers in Virology and 5 papers in Emergency Medicine. Recurrent topics in Catherine Granier's work include HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (7 papers) and HIV-related health complications and treatments (5 papers). Catherine Granier is often cited by papers focused on HIV/AIDS drug development and treatment (9 papers), HIV Research and Treatment (7 papers) and HIV-related health complications and treatments (5 papers). Catherine Granier collaborates with scholars based in United Kingdom, United States and Germany. Catherine Granier's co-authors include Brian Wynne, Keith A. Pappa, Sharon Walmsley, Sherene Min, Franco Maggiolo, Dan Duiculescu, Laurent Hocqueloux, Antonio Antela, Nathan Clumeck and Uriel Sandkovsky and has published in prestigious journals such as New England Journal of Medicine, AIDS and JAIDS Journal of Acquired Immune Deficiency Syndromes.

In The Last Decade

Catherine Granier

10 papers receiving 959 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

2013 593 citations Sharon Walmsley, Antonio Antela et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Catherine Granier United Kingdom	8	908	699	267	141	84	10	976
Kati Vandermeulen Belgium	12	651 0.7×	480 0.7×	177 0.7×	133 0.9×	45 0.5×	19	713
Cynthia Brinson United States	18	1.3k 1.5×	1.0k 1.4×	449 1.7×	333 2.4×	98 1.2×	36	1.5k
Nicholaos Bellos United States	11	825 0.9×	621 0.9×	312 1.2×	134 1.0×	29 0.3×	15	936
Hal Martin United States	21	1.6k 1.8×	1.2k 1.7×	838 3.1×	252 1.8×	90 1.1×	44	1.8k
Simona Landonio Italy	17	615 0.7×	335 0.5×	256 1.0×	203 1.4×	16 0.2×	32	776
José Valdez Madruga Brazil	7	775 0.9×	600 0.9×	154 0.6×	181 1.3×	47 0.6×	11	829
Naomi Givens United Kingdom	9	566 0.6×	399 0.6×	200 0.7×	107 0.8×	35 0.4×	17	609
Awny Farajallah United States	8	599 0.7×	408 0.6×	243 0.9×	85 0.6×	19 0.2×	12	649
Daniel Seekins United States	19	532 0.6×	324 0.5×	161 0.6×	211 1.5×	62 0.7×	30	746
Simiso Sokhela South Africa	12	606 0.7×	326 0.5×	484 1.8×	132 0.9×	37 0.4×	31	791

Countries citing papers authored by Catherine Granier

Since Specialization

Citations

This map shows the geographic impact of Catherine Granier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Catherine Granier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Catherine Granier more than expected).

Fields of papers citing papers by Catherine Granier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Catherine Granier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Catherine Granier. The network helps show where Catherine Granier may publish in the future.

Co-authorship network of co-authors of Catherine Granier

This figure shows the co-authorship network connecting the top 25 collaborators of Catherine Granier. A scholar is included among the top collaborators of Catherine Granier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Catherine Granier. Catherine Granier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Yılmaz, Gürdal, Jesus Abraham Simón Campos, Keith Pietropaolo, et al.. (2023). Oral Bemnifosbuvir (AT-527) Vs Placebo in Patients With mild-to-moderate COVID-19 in an Outpatient Setting (MORNINGSKY). Future Virology. 18(13). 839–853. 7 indexed citations

Trottier, Benoît, Jordan E. Lake, Cynthia Brinson, et al.. (2016). Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study. Antiviral Therapy. 22(4). 295–305. 82 indexed citations

Tebas, Pablo, Princy Kumar, Charles B. Hicks, et al.. (2015). Greater change in bone turnover markers for efavirenz/emtricitabine/tenofovir disoproxil fumarate versus dolutegravir + abacavir/lamivudine in antiretroviral therapy-naive adults over 144 weeks. AIDS. 29(18). 2459–2464. 27 indexed citations

Cuffe, Robert L., Carly Barnett, Catherine Granier, et al.. (2015). Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir. HIV Clinical Trials. 16(5). 170–177. 1 indexed citations

Walmsley, Sharon, Axel Baumgarten, Juan Berenguer, et al.. (2015). Brief Report. JAIDS Journal of Acquired Immune Deficiency Syndromes. 70(5). 515–519. 160 indexed citations

Raffi, François, Anita Rachlis, Cynthia Brinson, et al.. (2014). Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials. AIDS. 29(2). 167–174. 43 indexed citations

Yazdanpanah, Yazdan, Laurent Hocqueloux, Gilles Pialoux, et al.. (2014). 48 week bone marker changes with Dolutegravir (DTG) plus Abacavir/Lamivudine (ABC/3TC) vs. Tenofovir/Emtricitabine/Efavirenz (EFV/TDF/FTC): the SINGLE trial. BMC Infectious Diseases. 14(S2). 1 indexed citations

Walmsley, Sharon, Antonio Antela, Nathan Clumeck, et al.. (2013). Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection. New England Journal of Medicine. 369(19). 1807–1818. 593 indexed citations breakdown →

Moyle, Graeme, Hans‐Jürgen Stellbrink, Juliet Compston, et al.. (2013). 96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naive, HIV-1-Infected Adults: Assert Study. Antiviral Therapy. 18(7). 905–913. 52 indexed citations

10.

Carosi, G., Adriano Lazzarin, Hans‐Juergen Stellbrink, et al.. (2009). Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naïve HIV-1–Infected Adult Subjects. HIV Clinical Trials. 10(6). 356–367. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact